You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

SODIUM IODIDE I 123 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Sodium Iodide I 123 patents expire, and when can generic versions of Sodium Iodide I 123 launch?

Sodium Iodide I 123 is a drug marketed by Cardinal Health 418, Curium, and Ge Healthcare. and is included in four NDAs.

The generic ingredient in SODIUM IODIDE I 123 is sodium iodide i-123. There are one thousand four hundred and seventy-two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the sodium iodide i-123 profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for SODIUM IODIDE I 123?
  • What are the global sales for SODIUM IODIDE I 123?
  • What is Average Wholesale Price for SODIUM IODIDE I 123?
Summary for SODIUM IODIDE I 123
US Patents:0
Applicants:3
NDAs:4
Finished Product Suppliers / Packagers: 2
Raw Ingredient (Bulk) Api Vendors: 6
Clinical Trials: 18
Patent Applications: 10
What excipients (inactive ingredients) are in SODIUM IODIDE I 123?SODIUM IODIDE I 123 excipients list
DailyMed Link:SODIUM IODIDE I 123 at DailyMed
Drug patent expirations by year for SODIUM IODIDE I 123
Recent Clinical Trials for SODIUM IODIDE I 123

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University Health Network, TorontoPhase 4
Stryker EndoscopyPhase 4
Osaka UniversityPhase 1

See all SODIUM IODIDE I 123 clinical trials

US Patents and Regulatory Information for SODIUM IODIDE I 123

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cardinal Health 418 SODIUM IODIDE I 123 sodium iodide i-123 CAPSULE;ORAL 018671-001 May 27, 1982 AA RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Ge Healthcare SODIUM IODIDE I 123 sodium iodide i-123 CAPSULE;ORAL 017630-003 Jan 8, 1993 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Curium SODIUM IODIDE I 123 sodium iodide i-123 CAPSULE;ORAL 071909-001 Feb 28, 1989 AA RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Ge Healthcare SODIUM IODIDE I 123 sodium iodide i-123 SOLUTION;ORAL 017630-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Cardinal Health 418 SODIUM IODIDE I 123 sodium iodide i-123 CAPSULE;ORAL 018671-002 May 27, 1982 AA RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Cardinal Health 418 SODIUM IODIDE I 123 sodium iodide i-123 CAPSULE;ORAL 018671-003 May 27, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Ge Healthcare SODIUM IODIDE I 123 sodium iodide i-123 CAPSULE;ORAL 017630-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

SODIUM IODIDE I 123 Market Analysis and Financial Projection Experimental

Sodium Iodide I-123: Market Dynamics and Financial Trajectory

Introduction

Sodium Iodide I-123 is a crucial radiopharmaceutical used primarily in diagnostic imaging and therapeutic applications, particularly in the field of nuclear medicine. This article delves into the market dynamics and financial trajectory of Sodium Iodide I-123, highlighting its current status, growth drivers, and future projections.

Current Market Valuation

As of 2023, the global sodium iodide market, which includes Sodium Iodide I-123, was valued at approximately USD 341.2 million[3].

Growth Drivers

Several factors are driving the growth of the sodium iodide market, including:

Increasing Demand in Healthcare

The rising prevalence of thyroid disorders, such as hyperthyroidism and thyroid cancer, is a significant driver. Approximately 20 million people in the United States alone are affected by thyroid disease, which has spurred demand for effective diagnostic solutions like Sodium Iodide I-123[4].

Advancements in Medical Imaging

Advancements in nuclear medicine and the growing use of molecular imaging techniques are enhancing the role of sodium iodide in radiopharmaceuticals. This includes the use of I-123 for thyroid scans, which are essential for diagnosing and managing thyroid conditions[4].

Government Support

Governments are investing heavily in healthcare infrastructure and research. For example, the U.S. government allocated USD 4.5 billion to nuclear medicine research in 2021, which indirectly benefits the sodium iodide market[3].

Emerging Markets

There is significant growth potential in emerging markets, particularly in regions like Asia-Pacific, Latin America, and Africa, where healthcare infrastructure is being developed and the demand for advanced diagnostic tools and therapies is increasing[3].

Market Segmentation

The sodium iodide market is segmented based on grade, formulation, purity level, application, and end-use.

Grade Segment

Industrial grade sodium iodide dominates the market, capturing around 64.7% of the market share by grade segment[3].

Formulation Segment

Crystalline sodium iodide is the most prevalent formulation, holding about 56.8% of the market share[3].

Purity Level Segment

High purity sodium iodide is the most sought-after, capturing around 48.4% of the market share by purity level segment[3].

Application Segment

Medical imaging is the leading application segment, accounting for about 34.5% of the market share. This includes the use of Sodium Iodide I-123 in thyroid scans and other diagnostic procedures[3].

End-Use Segment

The pharmaceutical industry is the largest end-user, capturing around 56.4% of the market share[3].

Financial Projections

The global sodium iodide market, including Sodium Iodide I-123, is expected to experience significant growth over the next decade.

Projected Market Size

By 2033, the global sodium iodide market is projected to reach around USD 622.7 million, growing at a Compound Annual Growth Rate (CAGR) of 6.2% from 2024 to 2033[3].

CAGR and Growth Rate

Different sources project slightly varying growth rates, but all indicate a robust CAGR. For instance, one projection suggests a CAGR of 6.3% from 2023 to 2031, while another estimates a CAGR of 7% from 2022 to 2028[3][4].

Sustainability and Eco-Friendly Trends

There is a growing emphasis on sustainability and environmental responsibility across various industries. Manufacturers of sodium iodide products are exploring sustainable production methods and eco-friendly packaging, which could provide a competitive edge in the market[1].

Collaborative Research and Development

Collaboration between industry players, research institutions, and academic organizations is crucial for accelerating innovation and driving product development in the sodium iodide market. Such initiatives can lead to the discovery of new applications, improved formulations, and enhanced product performance[1].

Clinical Use and Safety

Sodium Iodide I-123 is used in diagnostic imaging, particularly for thyroid scans. It is produced in a cyclotron and has a half-life of 13 hours. The compound is rapidly absorbed in the upper gastrointestinal tract and concentrates in the thyroid gland within 20-30 minutes[5].

Safety Considerations

While generally safe, Sodium Iodide I-123 can cause adverse reactions such as nausea, vomiting, and skin rashes. It is also important to note that it should be used with caution in pregnant women and nursing mothers due to its potential to affect fetal development and be excreted in human milk[2].

Key Takeaways

  • Market Growth: The global sodium iodide market is expected to grow significantly, driven by increasing demand in healthcare, advancements in medical imaging, and government support.
  • Segmentation: The market is dominated by industrial grade, crystalline formulation, high purity, and medical imaging applications.
  • Financial Projections: The market is projected to reach USD 622.7 million by 2033, growing at a CAGR of 6.2%.
  • Sustainability: There is a growing focus on sustainable production methods and eco-friendly packaging.
  • Collaborative Research: Collaboration between industry players and research institutions is key to driving innovation.

FAQs

What is the primary use of Sodium Iodide I-123?

Sodium Iodide I-123 is primarily used in diagnostic imaging, especially for thyroid scans, to visualize the function and structure of the thyroid gland.

What are the key drivers of the sodium iodide market growth?

The key drivers include the increasing prevalence of thyroid disorders, advancements in nuclear medicine, government support for healthcare research, and growing demand in emerging markets.

What is the projected market size of the global sodium iodide market by 2033?

The global sodium iodide market is projected to reach around USD 622.7 million by 2033.

What are the potential risks associated with the use of Sodium Iodide I-123?

Potential risks include adverse reactions such as nausea, vomiting, and skin rashes. It should also be used with caution in pregnant women and nursing mothers.

How is Sodium Iodide I-123 produced?

Sodium Iodide I-123 is produced in a cyclotron by bombarding Xenon-124 or Tellurium-123 with protons.

Sources

  1. Global Sodium Iodide Market to reach a valuation of USD 304 million by 2034 - FMI Projection. GlobeNewswire.
  2. Sodium Iodide 1-123. University of New Mexico.
  3. Sodium Iodide Market Size, Share | CAGR of 6.2%. Market.us.
  4. From Diagnostics to Therapeutics: The Growing Sodium Iodide Market. Market Research Intellect.
  5. I-123 Uptake | Treatment & Management | Point of Care - StatPearls. StatPearls.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.